In a comprehensive single-center analysis of 1294 PDAC patients, Neumann et al. confirmed that several hematological inflammation-based scores—namely, the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), C-reactive protein-to-albumin ratio (CAR), and the novel inflammatory benchmark index (IBI)—were all independent prognostic markers for overall survival, regardless of tumor stage or treatment intent [38]. This evidence concerns the gene CRP and neoplasm.